Last update Aug. 20, 2022
Very Low Risk
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Nicardipine Hydrochloride in other languages or writings:
Nicardipine Hydrochloride belongs to this group or family:
Main tradenames from several countries containing Nicardipine Hydrochloride in its composition:
|VD||2 - 8||l/Kg|
|Tmax||0.5 - 2||hours|
|M/P ratio||0.06 - 0.3||-|
|Theoretical Dose||0.0008 - 0.003||mg/Kg/d|
|Relative Dose||0.08 - 0.18||%|
|Ped.Relat.Dose||0.1 - 0.4||%|
Write us at email@example.com
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
It is a dihydropyridine-type calcium channel blocker with actions similar to those of nifedipine. It is used in the treatment of hypertension, angina pectoris, postoperative hypertension, and severe preeclampsia. Oral administration three times a day or intravenous infusion.
Its excretion into breast milk is almost null (undetectable in 82% of cases) or in clinically non-significant amount. (Matsumura 2014, Bartels 2007, Jarreau 2000), possibly due to its high percentage of plasmatic protein binding and very wide volume of distribution.
Several medical societies and expert authors consider the use of this medication possible during breastfeeding. (Hale, LactMed, Briggs 2015, Schaefer 2015, Serrano 2015)